Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
3 high-conviction SMID-cap biotech stocks to buy: Jefferies
October 1, 2026 3:00 PM EDTJefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.
The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).
Analyst Andrew Tsai said a tougher macro... More



